PDT Partners’s CRISPR Therapeutics CRSP Stock Holding History

PDT Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-50,060	Closed	-$2.7M	–	735
2024 Q2	$2.7M	Buy	50,060 +32,654	+188%	+$1.89M	0.26%	130
2024 Q1	$1.19M	Buy	+17,406	New	+$1.25M	0.11%	299
2023 Q1	–	Sell	-26,965	Closed	-$1.1M	–	596
2022 Q4	$1.1M	Buy	26,965 +4,045	+18%	+$215K	0.18%	197
2022 Q3	$1.5M	Sell	22,920 -3,818	-14%	-$277K	0.23%	120
2022 Q2	$1.63M	Buy	26,738 +18,239	+215%	+$1.07M	0.14%	224
2022 Q1	$533K	Buy	+8,499	New	+$534K	0.05%	568
2021 Q4	–	Sell	-7,906	Closed	-$885K	–	893
2021 Q3	$885K	Buy	+7,906	New	+$993K	0.06%	366
2021 Q1	–	Sell	-5,300	Closed	-$811K	–	793
2020 Q4	$811K	Buy	+5,300	New	+$626K	0.05%	365
2020 Q3	–	Sell	-3,215	Closed	-$236K	–	741
2020 Q2	$236K	Buy	+3,215	New	+$188K	0.02%	569

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PDT Partners's CRSP Position: Q3 2024 in Review

PDT Partners sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 50,060 shares — an estimated $2.7M sold.

PDT Partners first reported a position in CRSP in Q2 2020 and held it in 9 quarters. The position peaked at $2.7M in Q2 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

PDT Partners reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
PDT Partners sold 50,060 CRISPR Therapeutics shares in Q3 2024, an estimated $2.7M.
PDT Partners first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 9 quarters.
PDT Partners's CRISPR Therapeutics position peaked at $2.7M in Q2 2024.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on PDT Partners's 13F filing for Q3 2024, filed 14 Nov 2024.